Leukemia Inhibitory Factor Impairs the Function of Peripheral γδT Cells in Patients with Colorectal Cancer

References

• Avalle L, Camporeale A, Camperi A, Poli V. 2017. STAT3 in cancer: a double edged sword. Cytokine. 98:42–50.
   PubMed Web of Science ®Google Scholar
• Bian SB, Yang Y, Liang WQ, Zhang KC, Chen L, Zhang ZT. 2021. Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR–Hippo–YAP pathway. Ann N Y Acad Sci. 1484(1):74–89.
   PubMed Web of Science ®Google Scholar
• Cornel AM, Mimpen IL, Nierkens S. 2020. MHC class i downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers. 12(7):1760.
   PubMed Web of Science ®Google Scholar
• Dhatchinamoorthy K, Colbert JD, Rock KL. 2021. Cancer immune evasion through loss of MHC class i antigen presentation. Front Immunol. 12:636568.
   PubMed Web of Science ®Google Scholar
• Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N, et al. 2007. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 110(13):4319–30.
   PubMed Web of Science ®Google Scholar
• Godfrey DI, Le Nours J, Andrews DM, Uldrich AP, Rossjohn J. 2018. Unconventional T cell targets for cancer immunotherapy. Immunity. 48(3):453–73.
   PubMed Web of Science ®Google Scholar
• Golshani G, Zhang Y. 2020. Advances in immunotherapy for colorectal cancer: a review. Therap Adv Gastroenterol. 13:1756284820917527.
   Web of Science ®Google Scholar
• Gomes AQ, Martins DS, Silva-Santos B. 2010. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res. 70(24):10024–27.
   PubMed Web of Science ®Google Scholar
• Hodge DR, Hurt EM, Farrar WL. 2005. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 41(16):2502–12.
   PubMed Web of Science ®Google Scholar
• Johnson DE, O’Keefe RA, Grandis JR. 2018. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 15(4):234–48.
   PubMed Web of Science ®Google Scholar
• Kabelitz D, Serrano R, Kouakanou L, Peters C, Kalyan S. 2020. Cancer immunotherapy with γδ T cells: many paths ahead of us. Cell Mol Immunol. 17(9):925–39.
   PubMed Web of Science ®Google Scholar
• Li X, Lu H, Gu Y, Zhang X, Zhang G, Shi T, Chen W. 2020. Tim-3 suppresses the killing effect of Vγ9Vδ2 T cells on colon cancer cells by reducing perforin and granzyme B expression. Exp Cell Res. 386(1):111719.
   PubMed Web of Science ®Google Scholar
• Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M. 2009. Interleukin-17-producing γδ T cells selectively expand in response to pathogen products and environmental signals. Immunity. 31(2):321–30.
   PubMed Web of Science ®Google Scholar
• Meraviglia S, Lo Presti E, Tosolini M, La Mendola C, Orlando V, Todaro M, Catalano V, Stassi G, Cicero G, Vieni S, et al. 2017. Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer. Oncoimmunology. 6(10):e1347742.
   PubMed Web of Science ®Google Scholar
• Nicola NA, Babon JJ. 2015. Leukemia inhibitory factor (LIF). cytokine & growth factor reviews. Cytokine Growth Factor Rev. 26(5):533–44.
   PubMed Web of Science ®Google Scholar
• Pascual-Garcia M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, Cuartas I, Sala-Hojman A, Escudero L, Martinez-Ricarte F, et al. 2019. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun. 10(1):2416.
   PubMedGoogle Scholar
• Ramutton T, Buccheri S, Dieli F, Todaro M, Stassi G, Meraviglia S. 2014. γδ T cells as a potential tool in colon cancer immunotherapy. Immunotherapy. 6(9):989–99.
   PubMed Web of Science ®Google Scholar
• Salleh N, Giribabu N. 2014. Leukemia inhibitory factor: roles in embryo implantation and in nonhormonal contraception. Sci World J. 2014:201514.
   Google Scholar
• Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, et al. 2019. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature. 569(7754):131–35.
   PubMed Web of Science ®Google Scholar
• Silva-Santos B, Serre K, Norell H. 2015. γδ T cells in cancer. Nat Rev Immunol. 15(11):683–91.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–49.
   PubMed Web of Science ®Google Scholar
• Viswanadhapalli S, Dileep KV, Zhang KYJ, Nair HB, Vadlamudi RK. 2021. Targeting LIF/LIFR signaling in cancer. Genes Dis. 9(4):973–80. doi:10.1016/j.gendis.2021.04.003.
   PubMed Web of Science ®Google Scholar
• Wakita D, Sumida K, Iwakura Y, Nishikawa H, Ohkuri T, Chamoto K, Kitamura H, Nishimura T. 2010. Tumor-infiltrating IL-17-producing γδT cells support the progression of tumor by promoting angiogenesis. Eur J Immunol. 40(7):1927–37.
   PubMed Web of Science ®Google Scholar
• Won H, Moreira D, Gao C, Duttagupta P, Zhao X, Manuel E, Diamond D, Yuan YC, Liu Z, Jones J, et al. 2017. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. J Leukoc Biol. 102(2):423–36.
   PubMed Web of Science ®Google Scholar
• Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W, et al. 2014. γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity. 40(5):785–800.
   PubMed Web of Science ®Google Scholar
• Xi X, Li X, Wu F, Guan X, Jin L, Guo Y, Song W, Du B. 2017. Expression, purification and characterization of active untagged recombinant human leukemia inhibitory factor from E.Coli. Protein Expr Purif. 134:139–46.
   PubMed Web of Science ®Google Scholar
• Xie YH, Chen YX, Fang JY. 2020. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction Targeted Ther. 5(1):22.
   PubMed Web of Science ®Google Scholar
• Xu Y, Xiang Z, Alnaggar M, Kouakanou L, Li J, He J, Yang J, Hu Y, Chen Y, Lin L, et al. 2021. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 18(2):427–39.
   PubMed Web of Science ®Google Scholar
• Yu H, Yue X, Zhao Y, Li X, Wu L, Zhang C, Liu Z, Lin K, Xu-Monette ZY, Young KH, et al. 2014. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun. 5(1):5218–29.
   PubMedGoogle Scholar